ArticlePLoS pathogens2013
Dual expression profile of type VI secretion system immunity genes protects pandemic Vibrio cholerae.
Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 159 citations in OpenAlex.
- Repression of the Type VI Secretion System (T6SS) During Biofilm Formation Provides a Fitness Advantage forMicroorganisms · 2026Article
- Functional characterization of a pore-forming effector TseMt from the H4 type VI secretion system ofmLife · 2026Article
- Specific and broad-spectrum antibacterial effectors of type VI secretion system drive competition ofMicrobiology spectrum · 2026Article
- Type VI-secretion system-mediated competition and virulence in clinical and environmentalMicrobiology spectrum · 2026Article
- The transcription factor Vca0578 (DsvR) mediated expression of ZapC is required to promote cell division during lytic transglycosylase insufficiency inbioRxiv : the preprint server for biology · 2026Article
- The type VI secretion system and associated effector proteins.Nature reviews. Microbiology · 2026Review
- Tke5 is a Pseudomonas putida toxin that kills plant pathogens by depolarising membranes.Communications biology · 2026Article
- Structural insights into the antibacterial function of the Pseudomonas putida effector Tke5.The EMBO journal · 2026Article
- TseCurrent research in microbial sciences · 2026Article
- A widely-occurring family of pore-forming effectors broadens the impact of the Serratia Type VI secretion system.The EMBO journal · 2025Article
- Distinct immunity protein families mediate compartment-specific neutralization of a bacterial toxin.Cell reports · 2025Article
- Dissecting the antibacterial functions of the T6SS-2 cluster inApplied and environmental microbiology · 2025Article
- The Competitive Edge: T6SS-Mediated Interference Competition byMicroorganisms · 2025Review
- Comprehensive analysis of the type VI secretion system in Neisseria: identification, distribution, and evolutionary insights.BMC genomics · 2025Article
- Deployment of amBio · 2025Article
- A new class of type VI secretion system effectors can carry two toxic domains and are recognized through the WHIX motif for export.PLoS biology · 2025Article
- Distribution of the four type VI secretion systems in Pseudomonas aeruginosa and classification of their core and accessory effectors.Nature communications · 2025Article
- A widespread accessory protein family diversifies the effector repertoire of the type VI secretion system spike.Nature communications · 2024Article
- A coordinated attack by a bacterial secretion system and a small molecule drives prey specificity.Communications biology · 2024Article
- Use of zebrafish to identify host responses specific to type VI secretion system mediated interbacterial antagonism.PLoS pathogens · 2024Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The Vibrio cholerae type VI secretion system (T6SS) assembles as a molecular syringe that injects toxic protein effectors into both eukaryotic and prokaryotic cells. We previously reported that the V. cholerae O37 serogroup strain V52 maintains a constitutively active T6SS to kill other Gram-negative bacteria while being immune to attack by kin bacteria. The pandemic O1 El Tor V. cholerae strain C6706 is T6SS-silent under laboratory conditions as it does not produce T6SS structural components and effectors, and fails to kill Escherichia coli prey. Yet, C6706 exhibits full resistance when approached by T6SS-active V52. These findings suggested that an active T6SS is not required for immunity against T6SS-mediated virulence. Here, we describe a dual expression profile of the T6SS immunity protein-encoding genes tsiV1, tsiV2, and tsiV3 that provides pandemic V. cholerae strains with T6SS immunity and allows T6SS-silent strains to maintain immunity against attacks by T6SS-active bacterial neighbors. The dual expression profile allows transcription of the three genes encoding immunity proteins independently of other T6SS proteins encoded within the same operon. One of these immunity proteins, TsiV2, protects against the T6SS effector VasX which is encoded immediately upstream of tsiV2. VasX is a secreted, lipid-binding protein that we previously characterized with respect to T6SS-mediated virulence towards the social amoeba Dictyostelium discoideum. Our data suggest the presence of an internal promoter in the open reading frame of vasX that drives expression of the downstream gene tsiV2. Furthermore, VasX is shown to act in conjunction with VasW, an accessory protein to VasX, to compromise the inner membrane of prokaryotic target cells. The dual regulatory profile of the T6SS immunity protein-encoding genes tsiV1, tsiV2, and tsiV3 permits V. cholerae to tightly control T6SS gene expression while maintaining immunity to T6SS activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.